300725.SZ
300725.SZ
CNE1000035K5
PHARMABLOCK
Loading chart...

Company Profile

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.

Related stocks

688321.SS
688321.SS • China
SHENZHEN CHIPSCREEN BIOSCIENCES
24.31 CNY
1.61B USD 1Y -23.6%
300363.SZ
300363.SZ • China
PORTON
23.68 CNY
1.93B USD 1Y -9.3%
300601.SZ
300601.SZ • China
KANGTAI BIOLOGICAL
13.44 CNY
2.25B USD 1Y -20.6%
000766.SZ
000766.SZ • China
TONGHUA GOLDEN HORSE
14.97 CNY
2.16B USD 1Y -40.1%
603707.SS
603707.SS • China
NANJING KING-FRIEND BIOCHEMICAL
8.18 CNY
1.98B USD 1Y -21.6%
1681.HK
1681.HK • China
CONSUN PHARMA
14.85 HKD
1.59B USD 1Y -13.6%
600216.SS
600216.SS • China
ZHEJIANG MEDICINE
12.59 CNY
1.81B USD 1Y -12.9%
300723.SZ
300723.SZ • China
YPH
33.42 CNY
2.26B USD 1Y -40.6%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
53.2% p.a.
Max Drawdown (5Y)
-87.8%
Sharpe Ratio (5Y)
-0.48
Beta Factor
0.61
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 53.7 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (53.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -88.1% in the extended horizon.
ende